Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Mol Ther. 2007 Apr;9(2):190-6.Links

Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.

Kirman I, Whelan RL.

Columbia University, 630 VWest 168th Street, New York, NY 10032, USA. ik139@columbia.edu

Micromet Inc, in collaboration with Merck Serono SA, is developing adecatumumab for the potential treatment of adenocarcinomas, including breast and prostate cancer. Adecatunmumab is a fully human antibody targeting epithelial cell adhesion molecule (EpCAM). Adecatumumab is currently undergoing phase II clinical trials in breast and prostate cancer.

PMID: 17458174 [PubMed - indexed for MEDLINE]